Genetic Considerations in the Locoregional Management of Breast Cancer: a Review of Current Evidence

AbstractPurpose of ReviewBreast cancer is the most commonly diagnosed cancer and is the second leading cause of cancer death in women. Breast cancer screening has significantly improved detection of cancer and reduced mortality however, mortality has plateaued in recent years. As such, identifying ways to improve management decisions to further reduce mortality remains a high priority. Herein, we review the current evidence for locoregional management recommendations in patients with hereditary breast cancer mutations. Additionally, we discuss the potential utility of gene assays in locoregional management decision-making.Recent FindingsGene assays are currently used to identify patients who would benefit from systemic adjuvant therapy, and their uptake has improved clinical outcomes. There is growing evidence supporting their utility in determining patients at a higher risk for locoregional recurrence. As such, gene assays may have a role in decision-making regarding the locoregional management of breast cancer, and specifically the use of adjuvant RT.SummaryRisk reduction is central to the management of patients with hereditary breast cancer mutations. In patients with BRCA1/2 mutations, risk-reducing mastectomy (RRM) ± adjuvant radiotherapy (RT) or breast conserving therapy (BCS) with adjuvant RT is often an appropriate treatment regimen. A similar treatment approach is likely appropriate in other high-penetrance mutations, although RT should be used cautiously in patient...

Source: Current Breast Cancer Reports - February 28, 2023 Category: Cancer & Oncology Source Type: research